Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

NCT ID: NCT05369351

Last Updated: 2025-05-28

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-01-17
• Study Completion Date: 2026-11-10

Brief Summary

Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes without effective pharmacological treatment. Inflammation following ICH contributes to barrier disruption and peri-hematoma edema, leading to deterioration of neurological function. Preclinical evidence suggests that bone marrow hematopoietic stem and progenitor cells (HSPCs) are swiftly activated after ICH. Thereafter, these HSPCs produce an increased output of anti-inflammatory monocytes as an endogenous protective mechanism. Stimulation of β3 adrenergic receptor using selective agonists promotes the production of anti-inflammatory monocytes in bone marrow, and thereby reduces neuroinflammation, brain edema and neurological deficits. This study is to assess the safety and efficacy of a β3 adrenergic receptor agonist Mirabegron as a potential treatment option in ICH patients.

Detailed Description

This study is to evaluate the efficacy and safety of mirabegron in patients with intracerebral hemorrhage based on standard therapy

Conditions

Intracerebral Haemorrhage

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Standard treatment+mirabegron

In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.

Group Type: EXPERIMENTAL

Standard treatment+mirabegron

Intervention Type: DRUG

In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.

Standard treatment

Patients will receive usual care

Group Type: OTHER

Standard treatment

Intervention Type: OTHER

Standard treatment

Interventions

Standard treatment+mirabegron

In addition to standard treatment, the first dose of mirabegron 50mg/day will be given within 72 hours of symptom onset and continued until the 7th day after onset.

Intervention Type: DRUG

Standard treatment

Standard treatment

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Male or female patients aged above 18 years old.

2. The volume of the hematoma is 5-30 ml (including the cerebral cortex; Putamen, thalamus, caudate nucleus and related deep tracts; Cerebellar hemorrhage), which determined by CT scan.

3. The onset of cerebral hemorrhage symptoms or the time from last normal to detection is not more than 72 hours.

4. Patients with Glasgow Coma Scale (GCS) score ≥6 and < 12.

5. Before the onset of the disease, function was independent and mRS score<1.

6. Able and willing to sign written informed consent and comply with the requirements of the research protocol.

Exclusion Criteria

1. Multifocal cerebral hemorrhage, brain stem hemorrhage, or ventricular hemorrhage.

2. Secondary cerebral hemorrhage caused by aneurysm, brain tumor, arteriovenous malformation, thrombocytopenia, coagulation disorder, traumatic brain injury, etc.

3. Patients who require hematoma removal surgery or other emergency surgical interventions (such as decompressive craniectomy), or who are critically ill and close to death.

4. Patients who interfere with drug use due to nausea or vomiting.

5. Combined with the following conditions that preclude participation in the study due to other systemic diseases: Severe hepatic or renal impairment, atrial fibrillation or tachycardia, pulmonary infection, severe urinary tract infection, severe urinary tract obstruction, medically uncontrolled hypertension (systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg), pregnant and lactating women, and a history of malignant tumors within 5 years.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tianjin Medical University General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Qiang Liu

Professor of Neurology Department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Handong Li

Role: CONTACT

handongli90@foxmail.com

+8615022439149

Facility Contacts

Handong Li

Role: primary

handongli90@foxmail.com

+8615022439149

Other Identifiers

IRB2022-YX-073-01

Identifier Type: -

Identifier Source: org_study_id